Abstract
There has been an increase in understanding molecular biology of malignant pleural mesothelioma. This resulted in more clinical trials of novel therapeutic approaches. The more conventional systemic treatments for malignant mesothelioma are based on the use of Cisplatin and Pemetrexed. The newer agents such as vorinostat an Histone deacetylase inhibitor, focal adhesion kinase inhibitor Defactinib, mTOR inhibitor Everolimus, Bevacizumab a monoclonal antibody directed against Vascular Endothelial Growth Factor, immune check-point inhibitors, mesothelin targeted antibodies, Amatuximab have been investigated for their potential role in treatment of malignant mesothelioma. The role of radiation therapy in the curative treatment of malignant pleural mesothelioma has not been conclusively determined. In this review we will discuss the application of both radical and palliative radiotherapy in the context of managing of malignant mesothelioma.
Keywords: Chemotherapy, malignant mesothelioma, radiotherapy.
Current Respiratory Medicine Reviews
Title:The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Volume: 12 Issue: 3
Author(s): Michael Lind, Rachael Barton, Andrzej Wieczorek, Mahmoud Loubani and Jack A. Kastelik
Affiliation:
Keywords: Chemotherapy, malignant mesothelioma, radiotherapy.
Abstract: There has been an increase in understanding molecular biology of malignant pleural mesothelioma. This resulted in more clinical trials of novel therapeutic approaches. The more conventional systemic treatments for malignant mesothelioma are based on the use of Cisplatin and Pemetrexed. The newer agents such as vorinostat an Histone deacetylase inhibitor, focal adhesion kinase inhibitor Defactinib, mTOR inhibitor Everolimus, Bevacizumab a monoclonal antibody directed against Vascular Endothelial Growth Factor, immune check-point inhibitors, mesothelin targeted antibodies, Amatuximab have been investigated for their potential role in treatment of malignant mesothelioma. The role of radiation therapy in the curative treatment of malignant pleural mesothelioma has not been conclusively determined. In this review we will discuss the application of both radical and palliative radiotherapy in the context of managing of malignant mesothelioma.
Export Options
About this article
Cite this article as:
Lind Michael, Barton Rachael, Wieczorek Andrzej, Loubani Mahmoud and Kastelik A. Jack, The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma, Current Respiratory Medicine Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573398X12666160919115534
DOI https://dx.doi.org/10.2174/1573398X12666160919115534 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Chronic obstructive pulmonary disease (COPD) from childhood to adulthood: from the past to the future
Chronic obstructive pulmonary disease (COPD) is one of the three leading causes of death worldwide, with a major prevalence in low- and middle-income countries, resulting in a high social and economic cost. It is a heterogeneous respiratory disease, treatable and preventable, that causes persistent and often progressive airway obstruction in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Filling the Gaps between the In Vivo and In Vitro Microenvironment: Engineering of Spheroids for Stem Cell Technology
Current Stem Cell Research & Therapy Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology
Current Pharmaceutical Biotechnology Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via Modulation of Key Cell Signaling Networks
Recent Patents on Anti-Cancer Drug Discovery Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy subject Index To Volume 1
Current Molecular Medicine Patent Selections
Recent Patents on Biomarkers Regulating miRNAs Expression by Resveratrol: Novel Insights based on Molecular Mechanism and Strategies for Cancer Therapy
Current Molecular Pharmacology Role of Pemetrexed and Platinums Combination in Patients with Non- Small Cell Lung Cancer
Current Drug Targets Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Tip60: Main Functions and Its Inhibitors
Mini-Reviews in Medicinal Chemistry Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Tumor Homing Peptides as Molecular Probes for Cancer Therapeutics, Diagnostics and Theranostics
Current Medicinal Chemistry